June 19, 2025

Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds

Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to h...

The ASCO Post

June 18, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

June 13, 2025

Relacorilant and Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

In a phase III trial (ROSELLA) reported in The Lancet, Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorila...

The ASCO Post

June 10, 2025

Recent Advances in Treating Diffuse Large B-Cell Lymphoma

The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma and included both lymphomas...

The ASCO Post

June 10, 2025

Castor Oil

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. ...

The ASCO Post

May 28, 2025

Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD

Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual ...

The ASCO Post

May 23, 2025

W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of OSUCCC-James

Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohi...

The ASCO Post

May 23, 2025

The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts

In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level and rescinding Biden Administration order...

The ASCO Post

November 27, 2023

Expert Point of View: Helena Linardou, MD, PhD

Dr. Linardou presents promising findings on TROP-2-targeting agents for lung cancer at the 2023 World Conference on Lung Cancer, highlighting the potential to replace chemotherapy in first-line combinations.

The ASCO Post